April 11, 2007 – After the closing bell, Genentech reported an earnings increase of 68%; Cell Genesys raised $60 million by selling 10.8 million common shares and 2.2 million warrants; Vical reported that Vaxfectin, its vaccine adjuvant, provided a 60-fold boost to flu vaccines in mice; Nuvelo reported positive preclinical data for its Crohns disease drug; Genaera cut its headcount by 30%; a trial of Revlimid from Celgene was halted, though the reason for the stop was not disclosed; and Roche signed a deal worth up to 195 million euros with French biotech Transgene S.A. The AMEX Biotech index fell .38%. More details...
